Atlas Trials

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Clinical trial NCT03381066 · UNKNOWN

Trial details

NCT number
NCT03381066
Sponsor
Yonsei University
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Completely Resected NSCLC With Common EGFR Mutations
Start date
2018-04-10
Primary completion
2022-12-01
Enrollment
225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.